What is the dead-space loss per draw with a 29G needle at 10 mg/mL?

For reference: a 29G needle · 10 mg/mL.

I would like the arithmetic checked rather than the conclusion asserted.

I have deliberately not used an online calculator because I want to be able to check the result.

What is the general form of this calculation?

The distinction that resolves most of these questions is understanding that dead space is a fixed volume — typically 3 to 5 µL in a fixed-needle syringe and 35 to 100 µL in a luer-lock — and its cost scales with how small your draws are.

Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.

More usefully, corollary that follows immediately: changing needle gauge or length barely changes your losses.

The caveat is that dead space is a yield loss and not a dose-accuracy loss, so the person feeling this loss most is the person with the most total draws.

Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.

Before anything else: understand that dead space is a property of the syringe architecture, not of the needle gauge.

Dead space quantified: a fixed-needle insulin syringe holds roughly 3 to 5 µL in the hub and needle after the plunger bottoms out. A luer-lock syringe with a detachable needle holds 35 to 100 µL depending on the hub design.

Be sceptical of anything advertised as low dead space that retains a conventional plunger tip: if you can look into the fitting with the plunger fully forward and see an open conical void, that void is your dead space.

I would not underestimate the dead-space cost when calculating your true cost per dose.

If cost matters, this is the first thing to change, not the last.

The short answer is that dead space is small in absolute terms and huge as a fraction of a small dose, which is why it feels like a rounding error and behaves like a systematic loss.

The luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.

The relevant detail is that the needle lumen volume is under a microlitre in a typical fine-gauge configuration, so the needle is not the problem.

One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.

The switch nearly doubles your vial, which is better than most other optimisations combined.

edited 8 Dec 2024 by ines_brandt — removed a claim I could not source

In practice, this is arithmetic, so let us do the arithmetic and see where the losses actually are.

At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.

Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.

Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.

It helps to be literal here: dead space is the volume trapped in the syringe hub and needle after the plunger bottoms out, and it is the reason your 10 mg vial yields only 9.5 mg of usable draws.

Delivered peptide = 10 x 0.5 mg = 5.0 mg. Lost to dead space = 10 x 84 µL = 840 µL x 0.005 = 4.2 mg. Yield = 50 per cent.

Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.

If cost matters, this is the first thing to change, not the last.